Leidos Awarded Contract By Naval Medical Logistics Command

Company to Provide Research and Development Services for the Behavioral Sciences and Epidemiology Department

News provided by

Mar 10, 2014, 07:50 ET

RESTON, Va., March 10, 2014 /PRNewswire/ -- Leidos (NYSE: LDOS), a national security, health and engineering solutions company, was awarded a prime contract, Behavioral Epidemiology Assessment Research (BEAR), by the Naval Medical Logistics Command to provide research services for multiple behavioral health and epidemiology projects that support the Naval Health Research Center's (NHRC) Behavioral Sciences and Epidemiology Department. The single-award cost-plus fixed-fee (CPFF) contract has a one-year base period of performance, four one-year options and a total contract value of approximately $7.3 million, if all options are exercised. Work will be performed primarily in San Diego, Calif.

The NHRC's Behavioral Sciences and Epidemiology Department is dedicated to the study of behavioral trends that impact warfighter readiness. The department examines operationally relevant issues affecting personnel such as combat and operational stress, posttraumatic stress, misconduct, substance use, suicide and career-span health and wellness issues. Under this contract, Leidos will conduct behavioral and epidemiological investigations that address these and other deployment-related health issues. Specific examples of these studies may include determining factors related to the onset of mental disorders in military personnel; mental health surveillance of combat-deployed personnel; assessing the effects of adverse lifestyle behaviors on health, performance, and healthcare costs; and investigating the effects of acute stress on military personnel.

"Finding ways to improve the health and wellness of our military personnel and their families is important to the Nation, which means it's important to Leidos," said Steve Comber, President of Leidos Health. "We are pleased to continue our support of NHRC to help ensure our military is prepared to perform every mission."

About Leidos Health
As an industry leader for more than 25 years in the healthcare industry, Leidos Health fuses some of the world's most advanced technologies with the brightest minds in science, research and consulting. Today, Leidos is focused on developing next-generation solutions in areas such as biomedical research, public health, and health analytics to turn data into actionable information for clinicians and their patients. From leading groundbreaking medical research to fight diseases such as cancer, AIDS, and malaria, to implementing and optimizing electronic health records that enhance the research process and improve critical efficiencies – Leidos' passion to improve patient care and reduce costs is helping to transform healthcare. For more information, visit www.Leidos.com/health. For more information on how Leidos supports behavioral health research and outreach, visit http://www.leidos.com/health/healthservices/outreach-training.html.

About Leidos
Leidos is a science and technology solutions leader working to address some of the world's toughest challenges in national security, health, and engineering. The Company's 23,000 employees support vital missions for our government and the commercial sector, develop innovative solutions to drive better outcomes, and defend our Nation's digital and physical infrastructure from 'new world' threats. Leidos is headquartered in Reston, Va. and had approximately $6 billion in revenues for fiscal year 2013, on a pro forma basis, following the spin-off of the company's technical, engineering and enterprise IT business on Sept. 27, 2013. For more information, visit www.Leidos.com.

Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in Leidos' Annual Report on Form 10-K for the period ended January 31, 2013, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.